ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2003, 'No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001', AIDS, 17, pp. 264 - 267
,2003, 'Polyclonal proliferation and apoptosis of CCR5+ T Lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2', Journal of Infectious Diseases, 187, pp. 1735 - 1735
,2003, 'Rates of transmission of antiretroviral drug resistant strains of HIV-1', Journal of Clinical Virology, 26, pp. 153 - 153
,2002, 'Structured treatment interruption and beyond', BIOFUTUR, pp. 52 - 58, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000180098300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Supervised or structured treatment interruption (STI) and beyond...', Biofutur, pp. 52 - 58
,2002, 'Characterization of CD4(+) CTLs ex vivo', Journal of Immunology, 168, pp. 5954 - 5958
,2002, 'Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection', Virology, 304, pp. 246 - 264
,2002, 'Dyslipidemia due to retroviral protease inhibitors', Nature Medicine, 8, pp. 308 - 308, http://dx.doi.org/10.1038/nm0402-308a
,2002, 'Optimization of peptide linker length in production of MHC Class II/peptide tetrameric complexes increases yield, stability and allows identification of antigen specific CD4+ T cells in PBMC', European Journal of Immunology, 32, pp. 3366 - 3375
,2002, 'STI and beyond: the prospects of boosting anti-HIV immune responses', Trends in Immunology, 23, pp. 456 - 460
,2001, 'Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes', AIDS Research and Human Retroviruses, 17, pp. 1063 - 1066, http://dx.doi.org/10.1089/088922201300343744
,2001, 'Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses', Journal of Experimental Medicine, 193, pp. 375 - 385, http://dx.doi.org/10.1084/jem.193.3.375
,2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366
,2001, 'Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modelling.', AIDS Research and Human Retroviruses, 17, pp. 147 - 159
,2000, 'Functions of tetramer-stained HIV-specific CD4+ and CD8+ T cells', Current Opinion in Immunology, 12, pp. 370 - 374, http://dx.doi.org/10.1016/S0952-7915(00)00102-3
,2000, 'Memory CD8+ T cells in HIV infection', Philosophical Transactions of the Royal Society B: Biological Sciences, 355, pp. 363 - 367, http://dx.doi.org/10.1098/rstb.2000.0575
,2000, 'Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes', Proceedings of the National Academy of Sciences of the United States of America, 97, pp. 3382 - 3387, http://dx.doi.org/10.1073/pnas.97.7.3382
,2000, 'Cytotoxic T lymphocyte responses to human immunodeficiency virus: Control and escape', Stem Cells, 18, pp. 230 - 244, http://dx.doi.org/10.1634/stemcells.18-4-230
,2000, 'Highly active antiretroviral therapy for primary HIV-1 infection preserves immune function of virus-specific T lymphocytes', Quarterly Journal of Medicine, 93, pp. 769 - 769
,2000, 'Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection', AIDS, 14, pp. 2543 - 2551
,1999, 'The arrival of HLA class II tetramers', Journal of Clinical Investigation, 104, pp. 1669 - 1770, http://dx.doi.org/10.1172/jci8943
,1999, 'Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects', Clinical and Experimental Immunology, 115, pp. 147 - 152
,1999, 'Potent antiretroviral therapy of primary HIV-1 infection: partial normalisation of T lympho-cyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia.', Journal of Infectious Diseases, 180, pp. 320 - 329
,1999, 'Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific CTL activity in asymptomatic HIV infected individuals.', AIDS Research and Human Retroviruses, 15, pp. 105 - 113
,1998, 'Oligoclonal expansions of CD8+ T cells in chronic HIV infection are antigen specific', Journal of Experimental Medicine, 188, pp. 785 - 790, http://dx.doi.org/10.1084/jem.188.4.785
,1998, 'A model of primary HIV-1 infection', Mathematical Biosciences, 154, pp. 57 - 85
,1998, 'Can Antiretroviral Therapy 'treat' Opportunistic Infections in Patients with HIV Infection', HIV Advances in Research and Therapy, 8
,1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91
,1998, 'Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection', Journal of Infectious Diseases, 178, pp. 1812 - 1815
,1998, 'Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects', AIDS, 12, pp. 175 - 182
,1997, 'Immunological effects of antiretroviral and immune therapies for HIV.', AIDS (London, England), 11 Suppl A
,1997, 'Diagnosis and treatment of primary HIV infection', J HIV Combination Therapy, pp. 49 - 56
,1997, 'Restoring Immune Function through Antiretroviral Therapy', Clinical Insight, pp. 1 - 1
,1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, 13, pp. 29 - 32
,1996, 'Effect of therapeutic vaccination (p24-VLP) and AZT on immunological markers in early HIV disease', AIDS, 10, pp. P137 - P137, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VU96300198&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1996, 'The association between CD38 expression on T cells and delayed type hypersensitivity (DTH) response including tuberculin reactivity in asymptomatic HIV seropositive individuals', AIDS, 10, pp. P114 - P114, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VU96300177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1996, 'Early HIV-induced immune deficiency', Medical Journal of Australia, 164, pp. 107 - 108, http://dx.doi.org/10.5694/j.1326-5377.1996.tb101366.x
,1996, 'Managing HIV. Part 1: Principles. 1.2 Strategies of care in managing HIV.', The Medical journal of Australia, 164, pp. 99 - 104, http://dx.doi.org/10.5694/j.1326-5377.1996.tb101364.x
,1996, 'Alterations in the immune response of HIV-infected subjects treated with an HIV specific protease inhibitor, ritonavir', Journal of Infectious Diseases, 173, pp. 321 - 329
,1996, 'CD8+ lymphocyte responses to antiretroviral therapy of HIV infection', Journal of acquired immune deficiency syndrome and human retrovirology, 13, pp. 320 - 326
,1996, 'HIV progression and the Immune System: Can HIV Be Eradicated from an Infected Individual', International Medical Press
,1996, 'Managing HIV:early HIV induced immune deficiency', Medical Journal of Australia, 164, pp. 107 - 108
,1994, 'Intractable headache as the presenting complaint of AIDS-related lymphoma confined to bone', Journal of Acquired Immune Deficiency Syndromes, 7, pp. 629 - 630
,1993, 'Radionuclide hepatobiliary scanning in patients with AIDS-related sclerosing cholangitis', Clinical Nuclear Medicine, 18, pp. 417 - 422, http://dx.doi.org/10.1097/00003072-199305000-00010
,1992, 'Immunoglobulin Therapy: Present Status', Present Therapeutics, pp. 39 - 46
,